The collaboration will combine Water’s optimum bed density (OBD) technology with Daiso’s Daisogel chromatography columns to create a scale-able platform that, the firms claimed, eliminates the need for method redevelopment.
Waters and Daiso also argue that their expertise in this area will be attractive to pharma and biotech manufacturers keen to control costs.
“As drug manufacturers invest significant amounts of money to manufacture new drug substances, they need solid commitments from established high quality process bulk suppliers with a long track record for synthesizing chromatographic media for drug purification processes.”